Affective Bipolar Disorder: Effective Prophylaxis With Low Doses of Lithium Carbonate

1984 ◽  
Vol 77 (6) ◽  
pp. 805-806 ◽  
Author(s):  
Theodore E. Edis
Keyword(s):  
Bipolar Disorder ◽  
Lithium Carbonate ◽  
Low Doses ◽  
Effective Prophylaxis

scholarly journals Low doses of lithium carbonate reduce melatonin light sensitivity in healthy volunteers

2005 ◽  
Vol 8 (2) ◽  
pp. 255-259 ◽  
Author(s):  
Karen T. Hallam ◽  
James S. Olver ◽  
Jennifer E. Horgan ◽  
Caroline McGrath ◽  
Trevor R. Norman
Keyword(s):  
Healthy Volunteers ◽  
Lithium Carbonate ◽  
Light Sensitivity ◽  
Low Doses

scholarly journals Thyrotoxicosis treatment with lithium corbanate. Cases reported

2021 ◽  
Vol 17 (3) ◽  
pp. 22-26
Author(s):  
I. A. Matsueva ◽  
A. B. Dalmatova ◽  
T. V. Andreychenko ◽  
E. N. Grineva
Keyword(s):  
Side Effects ◽  
Thyroid Gland ◽  
Thyroid Hormones ◽  
Toxic Hepatitis ◽  
Lithium Carbonate ◽  
Graves Disease ◽  
Allergic Reactions ◽  
Low Doses ◽  
Short Course ◽  
Toxic Goiter

Treatment of thyrotoxicosis caused by Graves’ disease or multinodular toxic goiter, is not difficult, in most cases, since the prescription of thionamides allows to normalize the level of thyroid hormones quickly and safety. But in a number of cases this therapy might be associated with serious side effects (agranulocytosis, toxic hepatitis, cholestasis), severe allergic reactions and also individual intolerance on thionamides. In such cases lithium carbonate is used, especially in severe thyrotoxic syndrome. It is known, that lithium can accumulate in the thyroid gland at a concentration 3–4 times higher than in the plasma. Perhaps, lithium uses Na+/I- ions. It can inhibit the synthesis and secretion thyroid hormones of thyroid gland. The article presents the cases reported the use of lithium carbonate in thyrotoxicosis treatment before thyroidectomy. Administering low doses of carbonate lithium (900 mg/ per day) renders significant decrease or normalization of thyroid hormones concentration within 7–14 days, thus it let perform thyroidectomy on the patients. No side effects have been identified with such a short course of lithium carbonate treatment.

Bipolar Disorder (BD) and Obsessive Compulsive Disorder (OCD) Comorbidty or Varied Episodes in the Same Disorder

2009 ◽  
Vol 24 (S1) ◽  
pp. 1-1
Author(s):  
E. Oral ◽  
E. Ozan ◽  
E. Deveci ◽  
N. Aydın ◽  
I. Kirpinar
Keyword(s):  
Bipolar Disorder ◽  
Depressive Symptoms ◽  
Lithium Carbonate ◽  
Treatment Resistant ◽  
Obsessive Compulsive ◽  
Obsessive Compulsive Symptoms ◽  
Compulsive Disorder ◽  
Manic Symptoms ◽  
Episodic Course ◽  
Depressive Episodes

Previous studies have suggested that OCD has comorbidity with bipolar disorder (BD) (1,2). We evaluated the three bipolar OCD cases.C1: Because of the OCD symptoms Chlomipramine was started. Her OCD symptoms improved in several days but manic symptoms was apeeared, switched to Lithium Carbonate. In her out patient exams, manic and obsessive compulsive symptoms were almost never observed simultaneously at the course.C2: In 2003, her complaints started as combined OCD and Manic symptoms, Risperidon and Lithium carbonate were started, manic and OCD symptoms improved. In 2005, OCD and Depressive symptoms appeared together. She got improved with Lithium Carbonate and Chlomipramine. She had one episode with obsessive and manic symptoms or obsessive and depressive symptoms every year till now. Her uncle had Depression and her aunt had Bipolar disorder.C3: Because of his OCD symptoms we prescribed SSRI and lower dose antipsychotic. At that time he hospitalized for his manic symptoms, his OCD was partially remitted. His manic symptoms improved with Lithium carbonate1200p/d. He had resistant obsessive compulsive symptoms and episodic manic symptoms. His father had M. Depressive episodes.Conclusion:Our cases suggest that bipolar OCD has episodic course, treatment resistant symtomatology, high family loading and high frequency of recurrence.

scholarly journals Profile of lithium carbonate use in patients with bipolar disorder in Colombia

Biomédica ◽  
2016 ◽  
Vol 37 ◽  
Author(s):  
Manuel Enrique Machado-Duque ◽  
Catalina Alzate-Carvajal ◽  
Kevin David Zapata ◽  
Jorge Enrique Machado-Alba
Keyword(s):  
Bipolar Disorder ◽  
Lithium Carbonate

Introducción. El litio es el medicamento de elección para el tratamiento del trastorno afectivo bipolar (TAB).Objetivo. Determinar el perfil de uso y reacciones adversas del litio, en pacientes con TAB en Colombia.Materiales y métodos. Estudio observacional de cohorte retrospectiva entre 1 enero y 31 diciembre 2013, se incluyeron pacientes con diagnóstico de TAB tratados con carbonato de litio en 25 ciudades colombianas, evaluando variables socio-demográficas, dosis del litio, comedicación, interacciones medicamentosas y reacciones adversas. Se hizo un análisis multivariado mediante.Resultados. Se hallaron 331 pacientes con edad promedio de 44,5±13,9 años, 59,2% fueron mujeres, la dosis promedio de litio: 898 ± 294 mg/día, el 22% tenían dosis inferiores a recomendadas; en promedio lo han recibido 38,0±39,5 meses (rango: 12-159 meses); solo al 13,5% les realizaron litemia. El 71,3% recibían terapia coadyuvante para TAB con otros medicamentos, especialmente clozapina (16,6%) y ácido valproico (16,6%). Las principales comorbilidades fueron hipotiroidismo (18,1%) e hipertensión arterial (12,7%). Se encontraron 390 interacciones medicamentosas potencialmente toxicas; se reportaron reacciones adversas en 1,2% de casos. Se halló asociación estadísticamente significativa con menor riesgo de recibir terapia combinada al ser tratado en las ciudades de Bogotá (OR:0,4, p=0,025), Cartagena (OR:0,3, p=0,015) e Ibagué (OR:0,3, p=0,025).Conclusiones. El litio se está utilizando en general a dosis e intervalos recomendados, pero un porcentaje significativo recibe dosis inferiores a las recomendadas y no fue posible contrastar el efecto con sus mediciones séricas. Se debe mejorar el reporte de reacciones adversas y medición de litemias en los pacientes con TAB en Colombia.

scholarly journals TRANSTORNO BIPOLAR: CAUSAS, SINTOMAS E FARMACOTERAPIA COM CARBONATO DE LÍTIO / BIPOLAR DISORDER: CAUSES, SYMPTOMS AND PHARMACOTHERAPY WITH LITHIUM CARBONATE

2021 ◽  
Vol 7 (1) ◽  
pp. 7628-7633
Author(s):  
Caio Silva de Queiroz ◽  
Victória Oliveirade Jesus ◽  
Rafaela Maianna Cruz de Castro Freitas ◽  
Karine Svetlana Sales Carrilho ◽  
Rayssa Gabrielle Pereira de Castro Bueno ◽  
...  
Keyword(s):  
Bipolar Disorder ◽  
Lithium Carbonate

Treatment of Bipolar Depression: A Survey of Canadian Psychiatrists

1997 ◽  
Vol 42 (3) ◽  
pp. 298-302 ◽  
Author(s):  
Verinder Sharma ◽  
Dwight S Mazmanian ◽  
Emmanuel Persad ◽  
Karen M Kueneman
Keyword(s):  
Bipolar Disorder ◽  
Serotonin Reuptake ◽  
Selective Serotonin Reuptake Inhibitors ◽  
Tricyclic Antidepressants ◽  
Treatment Approach ◽  
Bipolar Depression ◽  
Treatment Strategies ◽  
Lithium Carbonate ◽  
Somatic Therapy ◽  
Somatic Therapies

Objective This study was conducted to examine how Canadian psychiatrists manage bipolar depression. Method A questionnaire specific to the treatment of bipolar depression was mailed to 1639 active members of the Canadian Psychiatric Association. Results Seven hundred and sixty-six completed questionnaires were returned (46.7%). Most psychiatrists indicated that a combination of psychotherapy and somatic therapy was their preferred approach. For bipolar disorder, depressed, lithium carbonate and selective serotonin reuptake inhibitors (SSRIs) were the preferred treatment strategies. For substitution, tricyclic antidepressants (TCAs) were the favoured choice. Lithium carbonate was the preferred choice for augmentation and addition. Conclusion These findings indicate that a combination of psychotherapy and somatic therapy is the preferred treatment approach for bipolar depression. Lithium carbonate and SSRIs are the favoured somatic therapies.

Investigation of the impact of an ADCY2 polymorphism as a predictive biomarker in bipolar disorder, suicide tendency and response to lithium carbonate therapy: the first report from Iran

2020 ◽  
Vol 21 (14) ◽  
pp. 1011-1020
Author(s):  
Sara Sadat Aghabozorg Afjeh ◽  
Jamal Shams ◽  
Safar Hamednia ◽  
Behzad Boshehri ◽  
Amir Olfat ◽  
...  
Keyword(s):  
Bipolar Disorder ◽  
Suicide Ideation ◽  
Lithium Carbonate ◽  
Predictive Biomarker ◽  
Amplification Refractory Mutation System ◽  
Cerebral Endothelium ◽  
Mutation System ◽  
Bipolar Patients ◽  
The Impact

High rates of mortality due to both suicide and medical comorbidities in bipolar patients can be decreased through the administration of lithium, which affects the cerebral endothelium as well as neurons. To investigate the role of ADCY2 in risk of bipolar disorder, we genotyped the ADCY2 rs2290910 in bipolar patients and healthy controls using amplification refractory mutation system PCR. This polymorphism was associated with risk of bipolar disorder (odds ratio [OR]: 0.430; 95% CI: 0.296–0.624; p = 0.001). The C allele was more frequent in suicide ideation group compared other groups (OR: 2.7; 95% CI: 1.386–5.302; p = 0.004). The T allele was more frequent in suicide attempt group compared with suicide ideation group (OR: 0.238; 95% CI: 0.111–0.509; p = 0.001).

The rationale, design, and progress of two novel maintenance treatment studies in pediatric bipolarity

2000 ◽  
Vol 12 (3) ◽  
pp. 136-138 ◽  
Author(s):  
R.L. Findling ◽  
B.L. Gracious ◽  
N.K. McNamara ◽  
J.R. Calabrese
Keyword(s):  
Bipolar Disorder ◽  
Clinical Trials ◽  
Bipolar Disorders ◽  
Lithium Carbonate ◽  
University Hospitals ◽  
Clinical Research Center ◽  
Antidepressant Effects ◽  
The University ◽  
Subsyndromal Symptoms

ABSTRACTIntroduction: There are no definitively established acute or maintenance treatments for juvenile bipolar disorder.Method: Two randomized, blind, maintenance clinical trials in children and adolescents with bipolar disorders are ongoing at the University Hospitals of Cleveland/Case Western Reserve University Stanley Clinical Research Center for bipolar disorder. The first is comparing the safety and effectiveness of lithium carbonate (Li+) to divalproex sodium (VPA) for up to 76 weeks in youths with stabilized bipolar illness (type 1 or 2). The second study is designed to compare the efficacy of VPA to placebo in the acute management of subsyndromal symptoms of bipolar disorder (‘cyclotaxia’) and the prevention of the full syndrome in children at risk. Both studies use the prospective life-chart method as an outcome measure.Results: Sixty-six youths have received study medication as part of the trial that is comparing Li+ to VPA as a maintenance therapy. In addition, 32 youths have received blinded treatment as part of the ‘cyclotaxia’ prevention study. Combination Li+A/PA treatment appears generally well tolerated and seems to have robust anti-manic and antidepressant effects.Discussion: Since the blind has not been broken on either of these clinical trials, conclusions about the maintenance effectiveness of either VPA or Li+ in youths with bipolar disorder type 1 or 2 cannot be made yet. Similarly, it is unclear whether VPA is superior to placebo in genetically high-risk youths with cyclotaxia. The final results of these trials should provide valuable information about the treatment of juvenile bipolar disorders.

scholarly journals Using mitochondrial respiration inhibitors to design a novel model of bipolar disorder-like phenotype with construct, face and predictive validity

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
O. Damri ◽  
S. Asslih ◽  
N. Shemesh ◽  
S. Natour ◽  
O. Noori ◽  
...  
Keyword(s):  
Bipolar Disorder ◽  
Motor Activity ◽  
Cell Viability ◽  
Mitochondrial Respiration ◽  
Forced Swim Test ◽  
Intraperitoneal Administration ◽  
Low Doses ◽  
Immobility Time

AbstractWe mimicked mild mitochondrial-distress robustly reported in bipolar-disorder (BD) by chronic exposure to uniquely low doses of inhibitors of mitochondrial-respiration complexes in vitro and in vivo. Exposure of the neuronal-originating SH-SY5Y cells to very low dose (10 pM) rotenone, a mitochondrial-respiration complex (Co)I inhibitor, for 72 or 96 h did not affect cell viability and reactive oxygen species (ROS) levels. Yet, it induced a dual effect on mitochondrial-respiration: overshooting statistically significant several-fold increase of most oxygen-consumption-rate (OCR) parameters vs. significantly decreased all OCR parameters, respectively. Chronic low doses of 3-nitropropionic acid (3-NP) (CoII inhibitor) did not induce long-lasting changes in the cells’ mitochondria-related parameters. Intraperitoneal administration of 0.75 mg/kg/day rotenone to male mice for 4 or 8 weeks did not affect spontaneous and motor activity, caused behaviors associated with mania and depression following 4 and 8 weeks, respectively, accompanied by relevant changes in mitochondrial basal OCR and in levels of mitochondrial-respiration proteins. Our model is among the very few BD-like animal models exhibiting construct (mild mitochondrial dysfunction), face (decreased/increased immobility time in the forced-swim test, increased/decreased consumption of sweet solution, increased/decreased time spent in the open arms of the elevated plus maze) and predictive (reversal of rotenone-induced behavioral changes by lithium treatment) validity. Our rotenone regime, employing doses that, to the best of our knowledge, have never been used before, differs from those inducing Parkinson’s-like models by not affecting ROS-levels and cell-viability in vitro nor motor activity in vivo.

Sign in / Sign up

Export Citation Format

Share Document